exemestane (Aromasin)

DRUG3 trials

Sponsors

Pfizer, Biogen

Conditions

Breast CancerBreast NeoplasmsMetastatic Breast Cancer

Phase 2

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

CompletedNCT01004081

BiogenBreast Cancer

Start: 2009-11-30End: 2011-10-31Updated: 2015-10-02

Phase 3

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

CompletedNCT00036270

PfizerBreast Neoplasms

Start: 2001-08-31End: 2011-02-28Updated: 2015-10-28

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

CompletedNCT01237327

PfizerMetastatic Breast Cancer

Start: 2001-11-30End: 2009-12-31Updated: 2011-05-06

Related Papers

Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy–Resistant Early Breast Cancers

JCO Precision Oncology2019-05-101 citations

Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.

2018-06-0635 citations

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

2011-01-01258 citations